IN-14199 is under clinical development by HK inno.N and currently in Phase I for Constipation. According to GlobalData, Phase I drugs for Constipation have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IN-14199’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IN-14199 is under development for the treatment of chronic idiopathic constipation.
HK inno.N overview
HK inno.N, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients and prescription drugs. Its product portfolio includes EPOKINE for the treatment of renal anemia, Leukokine to treat neutropenia, Calmtop for the treatment of colorectal cancer, Movealoxin, Cinezolid, Omapone a parenteral nutrition product, and Pemta an infusion solution. HK inno.N is headquartered in Seoul, South Korea.
For a complete picture of IN-14199’s drug-specific PTSR and LoA scores, buy the report here.